In this video, Sally Moore, MD, Royal United Hospital, Bath, UK, discusses some updates on the use of carfilzomib, lenalidomide and dexamethasone (KRd) in patients with multiple myeloma at first relapse in a real-world setting. Dr Moore gives an overview on the efficacy of this regimen, including prolonged progression-free survival (PFS) and deepening of responses, as well as the toxicities associated with KRd treatment. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.